Collaborators will work on selective glucocorticoid receptor modulators.

Karo Bio and Zydus Cadila are working together to discover and develop selective glucocorticoid receptor modulators for the treatment of inflammatory diseases.

Under the three-year research collaboration Karo Bio will utilize its expertise in nuclear receptor drug discovery including structural biology, drug design, and compound characterization. Zydus Cadila will initiate a focused drug discovery and development program, undertaking preclinical studies, IND application filing, and clinical trials.

Both parties will equally share the costs and and rewards from this partnership.

Previous articleAMRI Expands Foothold in India with Acquistion of FineKem
Next articleSeaside Proffers $4.5M to Support Discovery Activities in Fragile X Syndrome at Vanderbilt